News

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, has expanded its phase II clinical study of a vaccine against Clostridium difficile infection (CDI) into the US. The trial,

Addex Pharmaceuticals has decided to end prematurely the migraine prevention study 206. Reportedly, the routine safety monitoring of blinded data in study 206, has revealed an incidence of

Repligen has received $731,000 in research funding to support the ongoing development of new treatments for Friedreich’s ataxia from the Muscular Dystrophy Association (MDA). The company said that

Genocea Biosciences (Genocea) has received a grant from the University of Pittsburgh Medical Center’s (UPMC) sexually transmitted infections (STI) cooperative research center for the development of vaccines for

Ablynx has initiated a double-blind, randomised, placebo-controlled Phase I study with ALX-0141, a nanobody targeting Receptor Activator of Nuclear Factor kappa B Ligand (RANKL), in healthy postmenopausal women.

Dr. Reddy’s has signed a Memorandum of Understanding (MoU) with the state of Louisiana on 7th December 2009, to expand its Shreveport operations with incentives and support from

Celgene has presented clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of Apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). The study was a 352-patient,

The Society of Chemical Manufacturers and Affiliates (SOCMA) will affiliate Bio-Process Systems Alliance (BPSA), an industry trade group that promotes the implementation of single-use biopharmaceutical manufacturing technologies. Joseph

Covance has opened new clinical development offices in Seoul, South Korea and Mumbai, India. The company has also expanded offices in Tokyo, Japan and Hong Kong, China, to